<br/>Prostate cancer is the most common cancer in men, with 1 in 7 men being diagnosed in their lifetime. Hsp90 is a key molecular chaperone involved in cell signaling, proliferation, and survival, and therefore a promising target for therapeutic intervention. Inhibition of Hsp90 suppresses androgen signaling, promoting degradation of client proteins resulting in apoptosis. Both gedunin and celastrol disrupt the function of Hsp90 through unique pathways. The co-chaperone Cdc37 mediates the loading of protein kinase onto Hsp90, and the natural product celastrol disrupts Cdc37-Hsp90 complex formation. The natural product gedunin inhibits p23 chaperoning activity, blocking its cellular interaction with Hsp90. Studies have shown the anticancer activities of gedunin on several lines of cancer including melanoma, prostate, and human breast cancer cells.<br/>Herein, a novel, folate functional magnetic nanomedicine encapsulated with Hsp90 targeting drug cocktail, gedunin and celastrol, will be used for effective treatment of cancer. This MR nanotheranostics will be specifically used as the targeted drug delivery platform to deliver drugs to tumor. In this study, gedunin and celastrol carrying iron-oxide nanoparticles was formulated for the targeted treatment of prostate cancer. Effective drug delivery using targeted nanomedicine formulations, and various biomolecular and cellular anti-tumor activity will be discussed in this presentation.

Drug cocktail-carrying Nanomedicine for the treatment of Cancer

2019 Spring National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.